Filing Flows › Tonix Pharmaceuticals Holding (TNXP) › Q2 2025
Tonix Pharmaceuticals Holding (TNXP) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 11, 2025
Tonix Pharmaceuticals Holding (TNXP) reported revenue of $2.0M for the second quarter 2025 (Q2 2025), -10% from a year earlier and -18% from the quarter before.
Tonix Pharmaceuticals Holding, Q2 2025: revenue $2.0M (-10% year over year), net loss $28.3M, operating cash flow −$14.8M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.0M | -18% | -10% |
| Operating profit | −$28.3M | — | — |
| Net earnings | −$28.3M | — | — |
| Operating cash flow | −$14.8M | — | — |
What changed
Revenue was $2.0M in Q2 2025, down 10% year over year and down 18% from the previous quarter. Zembrace Symtouch was the largest line at 79% of revenue. Zembrace Symtouch lost $157K year over year (down 9%), 75% of the total change.
Operating costs exceeded revenue by $28.3M, an operating margin of -1416.2%. Total costs fell 62% while revenue fell 10%. The fastest-growing cost line was SG&A (+116%). The quarter ended with a net loss of $28.3M, wider than the previous quarter's $16.8M loss.
Operating cash flow was −$14.8M. Non-cash charges added back $483K of depreciation and amortization and $1.4M of share-based compensation. Working capital and other items added $11.5M. Capital expenditures of $527K exceeded it, leaving free cash flow of −$15.4M.
Questions
What was Tonix Pharmaceuticals Holding's revenue in the second quarter 2025?
Tonix Pharmaceuticals Holding (TNXP) reported revenue of $2.0M for the second quarter 2025 (Q2 2025), -10% from a year earlier and -18% from the quarter before.